All Stories

  1. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2
  2. Trim28 acts as restriction factor of prototype foamy virus replication by modulating H3K9me3 marks and destabilizing the viral transactivator Tas
  3. The Manifold Roles of Sphingolipids in Viral Infections
  4. SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro
  5. Facile Synthesis and In Vitro Activity of N-Substituted 1,2-Benzisothiazol-3(2H)-ones against Dengue Virus NS2BNS3 Protease
  6. Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
  7. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue
  8. Towards a broad-spectrum antiviral, the myristoyltransferase inhibitor IMP-1088 suppresses viral replication – the Yellow fever NS5 is myristoylated
  9. The SARS-CoV-2 RNA–protein interactome in infected human cells
  10. A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells
  11. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2
  12. Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
  13. Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases
  14. Corrigendum to “Spumaretroviruses: Updated taxonomy and nomenclature” [Virology 516 (2018) 158–164]
  15. Spumaretroviruses: Updated taxonomy and nomenclature
  16. Low doses of cholera toxin and its mediator cAMP induce CTLA-2 secretion by dendritic cells to enhance regulatory T cell conversion
  17. Purification of foamy viral particles
  18. A purine-rich element in foamy virus pol regulates env splicing and gag/pol expression
  19. Sequence errors in foamy virus sequences in the GenBank database: resequencing of the prototypic foamy virus proviral plasmids
  20. Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: Inhibition kinetics and docking studies
  21. Novel Dengue Virus NS2B/NS3 Protease Inhibitors
  22. Obituary: Axel Rethwilm (1959–2014)
  23. Determination of the protease cleavage site repertoire—The RNase H but not the RT domain is essential for foamy viral protease activity
  24. Evolution of Foamy Viruses: The Most Ancient of All Retroviruses
  25. Foamy Virus Gag p71-p68 Cleavage Is Required for Template Switch of the Reverse Transcriptase
  26. Regulation of Retroviral Polyadenylation
  27. U1snRNP-mediated suppression of polyadenylation in conjunction with the RNA structure controls poly (A) site selection in foamy viruses
  28. Construction of a High Titer Infectious HIV-1 Subtype C Proviral Clone from South Africa
  29. A complex immunodeficiency is based on U1 snRNP-mediated poly(A) site suppression
  30. Mutations in HIV-1gagandpolCompensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease
  31. The prototype foamy virus protease is active independently of the integrase domain
  32. HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High
  33. Regulation of Foamy Virus Protease Activity by Viral RNA: a Novel and Unique Mechanism among Retroviruses
  34. Basic Residues in the Foamy Virus Gag Protein
  35. Regulation of Foamy Viral Transcription and RNA Export
  36. Regulation of foamy virus protease activity by viral RNA
  37. Foamy Virus Nuclear RNA Export Is Distinct from That of Other Retroviruses
  38. Complete nucleotide sequence and evolutionary analysis of a Gorilla foamy virus
  39. Formation of transient dimers by a retroviral protease
  40. Molecular Analysis of HIV Type 1 vif Sequences from Cape Town, South Africa
  41. Phylogenetic Diversity and Low Level Antiretroviral Resistance Mutations in HIV Type 1 Treatment-Naive Patients from Cape Town, South Africa
  42. Characterisation of a chikungunya virus from a German patient returning from Mauritius and development of a serological test
  43. Genotypic resistance testing in HIV by arrayed primer extension
  44. The complete nucleotide sequence of a New World simian foamy virus
  45. Acetylation of the foamy virus transactivator Tas by PCAF augments promoter-binding affinity and virus transcription
  46. From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease
  47. A peptide inhibitor of HIV-1 assembly in vitro
  48. Comparative functional characterization of the feline foamy virus transactivator reveals its species specificity
  49. The Mason-Pfizer Monkey Virus PPPY and PSAP Motifs Both Contribute to Virus Release
  50. Identification of protein phosphorylation sites by combination of elastase digestion, immobilized metal affinity chromatography, and quadrupole-time of flight tandem mass spectrometry
  51. Modification of Immobilized Peptides
  52. TIF-IA, the factor mediating growth-dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p
  53. Construction of Infectious Feline Foamy Virus Genomes: Cat Antisera Do Not Cross-Neutralize Feline Foamy Virus Chimera with Serotype-Specific Env Sequences
  54. Nuclear Localization of the Functional Bel 1 Transactivator but Not of the Gag Proteins of the Feline Foamy Virus
  55. Detection of Subgenomic cDNAs and Mapping of Feline Foamy Virus mRNAs Reveals Complex Patterns of Transcription
  56. A rapid streptavidin-capture ELISA specific for the detection of antibodies to feline foamy virus
  57. Regulation of gene expression by human foamy virus and potentials of foamy viral vectors